1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow EBV-Positive DLBCL, NOS: new trials by email Literature Review of EBV-Positive DLBCL, NOS trials Research Report on EBV-Positive DLBCL, NOS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas Nanatinostat in combination with valganciclovir - Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS | Phase 2 | Terminated | Viracta Therapeutics, Inc. | 102 | 2021-05-28 | 2025-07-28 |
Epstein-Barr Virus Infections (1) · Pyloric Stenosis, Hypertrophic (1)
DNA Virus Infections (1) · Digestive System Diseases (1) · Gastric Outlet Obstruction (1) · Gastrointestinal Diseases (1) · Herpesviridae Infections (1) · Infections (1) · Pyloric Stenosis (1) · Stomach Diseases (1) · Tumor Virus Infections (1) · Virus Diseases (1)
Valganciclovir (1)
Viracta Therapeutics, Inc. (1)
Australia (1) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Malaysia (1) · Singapore (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1) · United States (1)